Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2015 by Gynecologic Oncology Group.
Recruitment status was:  Active, not recruiting
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Gynecologic Oncology Group Identifier:
First received: December 6, 2000
Last updated: May 29, 2015
Last verified: May 2015

RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.

PURPOSE: This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer.

Condition Intervention Phase
Endometrial Cancer
Drug: fulvestrant
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Faslodex In Recurrent/Metastatic Endometrial Cancer

Resource links provided by NLM:

Further study details as provided by Gynecologic Oncology Group:

Primary Outcome Measures:
  • Clinical Response by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Evaluated Every 8 Weeks [ Time Frame: Response was measured every other cycle (every 8 weeks) until disease progression is documented or adverse events preclude further treatment. ]

    Primary outcome measured according to RECIST v1.0 Best Response:

    Complete Response (CR) is disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart

    Disease Progression is at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.

    Partial Response (PR) is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of nontarget lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required

    Stable Disease is any condition not meeting the above criteria.

    Indeterminate is defined as having no repeat tumor assessments following initiation of study therapy for reasons unrelated to symptoms or signs of disease.

  • Clinical Response by RECIST Criteria of Estrogen Receptor Expression [ Time Frame: Every other cycle (every 8 weeks) until disease progression is documented or adverse events preclude further treatment. ]

Secondary Outcome Measures:
  • Toxicity of Fulvestrant by Common Toxicity Criteria [ Time Frame: During study treatment and up to 30 days after stopping study ]

Enrollment: 67
Study Start Date: August 2004
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fulvestrant
Fulvestrant IM 250mg per month
Drug: fulvestrant

Detailed Description:


  • Compare the probability of clinical response in estrogen receptor (ER)-positive vs ER-negative patients with recurrent, persistent, or metastatic endometrial cancer treated with fulvestrant.
  • Compare the relationship between response rate and intensity of receptor expression in patients treated with this drug.
  • Determine the frequency and intensity of toxicity of this drug in these patients.

OUTLINE: Patients receive fulvestrant intramuscularly on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed recurrent, persistent, or metastatic endometrial cancer that is not curable with surgery or radiotherapy
  • Estrogen receptor (ER) and progesterone receptor status known by immunohistochemistry

    • ER positive or negative allowed
  • Measurable disease

    • At least 1 target lesion not within a previously irradiated field OR irradiated target lesion with clear disease progression
    • At least 20 mm by conventional techniques, including palpation, x-ray, CT scan, MRI, OR at least 10 mm by spiral CT scan



  • Not specified

Performance status:

  • GOG 0-1

Life expectancy:

  • Not specified


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥100,000/mm^3
  • No prior bleeding diathesis (disseminated intravascular coagulation, clotting factor deficiency, or requirement for anticoagulants)


  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • SGOT ≤ 3 times ULN
  • Alkaline phosphatase ≤ 3 times ULN


  • Creatinine ≤ 2 mg/dL


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No hypersensitivity to castor oil
  • No other concurrent malignancy except nonmelanoma skin cancer
  • No other prior malignancy within past 5 years


Biologic therapy:

  • Not specified


  • No prior chemotherapy for persistent, recurrent, or metastatic endometrial cancer
  • No more than 1 prior chemotherapy regimen for newly diagnosed endometrial cancer that has subsequently recurred

Endocrine therapy:

  • At least 3 weeks since prior hormonal therapy and recovered


  • See Disease Characteristics
  • At least 3 weeks since prior radiotherapy and recovered


  • See Disease Characteristics
  • At least 3 weeks since prior surgery and recovered
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00006903

  Show 52 Study Locations
Sponsors and Collaborators
Gynecologic Oncology Group
National Cancer Institute (NCI)
Study Chair: Allan Covens, MD Toronto Sunnybrook Regional Cancer Centre
  More Information

Responsible Party: Gynecologic Oncology Group Identifier: NCT00006903     History of Changes
Other Study ID Numbers: GOG-0188
NCI-2009-00581 ( Other Identifier: NCI )
Study First Received: December 6, 2000
Results First Received: May 20, 2014
Last Updated: May 29, 2015

Keywords provided by Gynecologic Oncology Group:
stage IV endometrial carcinoma
recurrent endometrial carcinoma
stage III endometrial carcinoma

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Hormones processed this record on May 25, 2017